FindTrial
Sign In

To Study the Efficacy of Directly Acting Antivirals In Patients of Hepatitis C Infection who are On Dialysis.

A Prospective Observational Study of Efficacy and Safety of Directly Acting Antivirals in Chronic Kidney Patients on Maintenance Hemodialysis with Chronic Hepatitis C Virus Infection.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/06/014408
Enrollment
34
Registered
2018-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Kideny Disease Patients on Hemodialysis With Hepatitis C infection Health Condition 2: N186- End stage renal disease

Interventions

Intervention1: NIL: NIL

Sponsors

INDRAPRASTHA APOLLO HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Chronic Kidney Disease on Hemodialysis with concomitant Hepatitis C infection with or without compensated Liver Cirrhosis

Exclusion criteria

Exclusion criteria: Patients with Decompensated Liver Cirrhosis 2) Patients with Significant alcohol intake history 3) Concomitant Chronic Hepatitis B infection or HIV infection 4) NASH 5) Pregnancy

Design outcomes

Primary

MeasureTime frame
Percentage of patients achieving the Sustained Virological response at 12 weeks post therapyTimepoint: 12 weeks post therapy—

Secondary

MeasureTime frame
a) To find out percentage of patients achieving the Virological response at end of therapy b) To find the incidence of adverse events of directly acting antivirals in patients with Chronic kidney disease on HaemodialysisTimepoint: At end of 12 week of therapy—

Countries

India

Contacts

Public ContactDr Pankaj Gote

Indraprastha Apollo Hospital

Pankajgote@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026